11 clinical trials found.
-
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
The goal of this Phase II study is to evaluate the safety/tolerability and clinical activity of the combination of nab-paclitaxel and the antibody against ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Multicenter Phase I/II Trial of Anastrozole Palbociclib Trastuzumab and Pertuzumab in HR-positive Her2-positive Metastatic Breast Cancer (ASPIRE)
The purpose of this study is to assess the safety and effectiveness of giving anastrozole, palbociclib, trastuzumab and pertuzumab to women with hormone receptor (HR ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
Site for EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
The purpose of the study is to determine the safety and tolerability of pre-operative therapy with 12 weeks of taxane, trastuzumab (or FDA approved biosimilar ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant hormone receptor positive HER2 negative metastatic breast cancer (FAC vs FA)
The purpose of the study is to determine the effects (good and bad) of adding copanlisib to the usual therapy of fulvestrant and abemaciclib in ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
An Open-label Multicenter Multicohort Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors
The purpose of the study is to assess the antitumor activity and safety of enfortumab vedotin as a single agent in adult subjects who have ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Phase Ib/II Multicenter Open-label Modular Dose-Finding and Dose Expansion Study to Explore the Safety Tolerability and Anti-tumor Activity of Trastuzumab Deruxtecan (DS-8201a T-DXd) in Combination with other Anti-cancer Agents in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)
The purpose of the study is to determine if study drug Trastuzumab Deruxtecan (T-DXd) can be given safely in combination with other cancer treatments to ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Global Phase 2 Study of ARX788 in HER2-positiveMetastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1 and/or T-DXd and/or Tucatinib-containing Regimens
The purpose of the study is to assess anticancer activity and safety of ARX788 in subjects with metastatic HER2-positive breast cancer who were previously treated ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Phase 1 Open Label Dose-Escalation and Expansion Study of Oral ORIN1001 with and without Chemotherapy in the Treatment of Subjects with Solid Tumors
The purpose of the study is to determine the recommended Phase 2 dose of ORIN1001 when given as a single agent as well as phase ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The purpose of the study is to determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
eMonarcHER: A Randomized Double Blind Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk Node-Positive HR+ HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
The purpose of the study is to determine and compare the efficacy of abemaciclib plus physician’s choice ET (endocrine therapy) versus placebo plus physician ...Phase
Interventional
TRIAL ROLE: Sub Investigator
